Startups
Spectron provides GMP, pharmaceutical grade Lu-177, Ac-225 and I-131 for various clinical applications. Spectron operates under a quality program that has been inspected by the FDA with approved drugs FDG, NaF and Ammonia. Spectron provides labeling and contract manufacturing services as it relates to Lu-177, Ac-225, I-131, I-124, I-111, Zr-89, Copper-64 and Fluorine-18.
Overview
Location
United States
Employees
11-50
Total raised
$85M
Founded date
2004
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 7, 2026 | SpectronRx Secures $85M for Radiopharmaceutical Growth | SpectronRx has announced that it has raised $85 million in funding from the New York private investment group OrbiMed. The injection of funding will be used for the gigantic expansion of the company’s MedIsotope manufacturing and contract m... |
| Mar 25, 2026 | Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics | SYDNEY, March 25, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment o... |
| Jun 17, 2025 | Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx | Highlights Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for 64Cu-SAR-bisPSMA. SpectronRx's facility in Indiana will provide on-demand commercial-scale manufacturing of both copper-64 and 64Cu-SAR-bisPSM... |
| Nov 1, 2022 | SpectronRx Names Peter Webner Chief Operating Officer | Share Tweet Share Share Email Fast-growing Indiana-based radiopharmaceutical developer and manufacturer appoints leading radiopharmaceutical executive to a new leadership role SpectronRx, a leading radiopharmaceutical contract development, ... |
| Nov 16, 2020 | Why contract development and manufacturing for radiopharma may be a smart move | One of the fastest-growing segments in the life sciences industry is that of radiopharmaceuticals, or what some call nuclear medicine. The global market for radiopharmaceuticals was valued at $6.1 billion in 2019 and is estimated to reach $... |
| Why contract development and manufacturing for radiopharma may be a smart move | One of the fastest-growing segments in the life sciences industry is that of radiopharmaceuticals, or what some call nuclear medicine. The global market for radiopharmaceuticals was valued at $6.1 billion in 2019 and is estimated to reach $... | |
| SpectronRx | “SpectronRx |” |
Reviews 0
FAQ about SpectronRx
When was SpectronRx founded?
SpectronRx was founded in 2004.
How much funding has SpectronRx raised?
SpectronRx has raised $85M in total across 1 funding round.
What has the press written about SpectronRx?
Parsers VC has collected 8 articles mentioning SpectronRx, among them “SpectronRx Secures $85M for Radiopharmaceutical Growth” (Apr 7, 2026) and “Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics” (Mar 25, 2026).
Is SpectronRx still active?
Yes, SpectronRx is active; its latest activity on Parsers VC dates from Apr 7, 2026.